9 results
This study will evaluate the efficacy, safety, and tolerability of sildenafil or placebo added to pirfenidone treatment (study treatments) in patients with advanced idiopathic pulmonary fibrosis (IPF) and intermediate or high probability of Group 3…
The purpose of the study is to test whether a centre-wide policy of incremental antibiotic therapy will reduce arrhythmia device infection in patients undergoing arrhythmia device procedures compared to a policy of conventional antibiotic…
Primary objectiveThe primary objective is to evaluate the effect of Pirfenidone on the change in FEV1 over 6 months in lung transplant recipients with BOS, who are treated with Azithromycin.Secondary objectives The secondary objectives involve the…
The main objective of the trial will be to assess safety and tolerability of combined treatmentwith nintedanib and pirfenidone.A secondary objective is to assess the exposure based on PK trough concentration values tonintedanib either given alone or…
to investigate the safety and tolerability of pirfenidone in asbestosis patients
In light of the above, our objective is to study the (cost-) effectiveness of a single intravenous gift of antibiotic prophylaxis with a firstgeneration cephalosporin prior to implant removal following surgical fixation of foot, ankle and/or lower…
The hypothesis is that a switch from intravenous to oral antimicrobial therapy is non-inferior to standard intravenous therapy in patients with low-risk SAB. Therefore, the primary objective of the trial is to demonstrate, that oral switch therapy (…
To provide high level of evidence that omitting perioperative antibiotic prophylaxis does not increase the postoperative infection rate, in patients with acute calculous cholecystitis undergoing laparoscopic cholecystectomy.
Lu AF28996 is an orally administered investigational compound of a potent, long-acting dopamine agonist, Lu AA40326, currently under development by H. Lundbeck A/S for the treatment of Parkinson*s disease (PD). Primary Objective:to investigate the…